lomitapide + dextromethorphan

Lomitapide + dextromethorphan refers to a theoretical or proposed combination of two small molecule drugs: lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor used primarily for the treatment of homozygous familial hypercholesterolemia (HoFH), and dextromethorphan, a cough suppressant and central nervous system agent with activity as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist. No approved combination product containing these two agents is currently known or described in the scientific or regulatory literature. Lomitapide reduces LDL cholesterol by inhibiting MTP and thus the synthesis of very low-density lipoprotein (VLDL), while dextromethorphan has roles in cough suppression and novel antidepressant combinations via NMDA antagonism and monoamine reuptake inhibition.